Rhumbline Advisers trimmed its stake in Incyte Corporation (NASDAQ:INCY) by 1.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 340,874 shares of the biopharmaceutical company’s stock after selling 3,593 shares during the period. Rhumbline Advisers owned about 0.16% of Incyte Corporation worth $39,794,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Fisher Asset Management LLC boosted its stake in Incyte Corporation by 3.2% in the second quarter. Fisher Asset Management LLC now owns 15,532 shares of the biopharmaceutical company’s stock worth $1,956,000 after purchasing an additional 482 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Incyte Corporation by 5.4% in the second quarter. State of Alaska Department of Revenue now owns 2,292 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 117 shares in the last quarter. Oregon Public Employees Retirement Fund acquired a new position in Incyte Corporation in the second quarter worth $2,242,000. LS Investment Advisors LLC boosted its stake in Incyte Corporation by 12.9% in the second quarter. LS Investment Advisors LLC now owns 5,595 shares of the biopharmaceutical company’s stock worth $704,000 after purchasing an additional 641 shares in the last quarter. Finally, Aperio Group LLC boosted its stake in Incyte Corporation by 11.4% in the second quarter. Aperio Group LLC now owns 52,330 shares of the biopharmaceutical company’s stock worth $6,589,000 after purchasing an additional 5,335 shares in the last quarter. Hedge funds and other institutional investors own 89.53% of the company’s stock.

In other Incyte Corporation news, EVP Eric H. Siegel sold 1,820 shares of Incyte Corporation stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $137.40, for a total value of $250,068.00. Following the completion of the sale, the executive vice president now owns 23,553 shares of the company’s stock, valued at approximately $3,236,182.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 714 shares of Incyte Corporation stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $124.25, for a total transaction of $88,714.50. Following the completion of the sale, the executive vice president now directly owns 15,496 shares of the company’s stock, valued at approximately $1,925,378. The disclosure for this sale can be found here. Insiders have sold 102,062 shares of company stock valued at $12,652,893 in the last three months. 17.70% of the stock is owned by insiders.

Several brokerages have recently issued reports on INCY. BidaskClub lowered Incyte Corporation from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co set a $149.00 price target on Incyte Corporation and gave the company a “buy” rating in a research note on Tuesday, August 1st. Barclays PLC reissued an “overweight” rating and issued a $165.00 target price (down previously from $180.00) on shares of Incyte Corporation in a research note on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $135.00 target price on Incyte Corporation and gave the company a “hold” rating in a research note on Tuesday, October 31st. Finally, Jefferies Group LLC restated a “buy” rating and issued a $148.00 price target on shares of Incyte Corporation in a report on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $144.98.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/16/rhumbline-advisers-lowers-stake-in-incyte-corporation-incy.html.

Incyte Corporation (NASDAQ INCY) traded up $1.36 during midday trading on Thursday, hitting $106.60. The company had a trading volume of 118,540 shares, compared to its average volume of 1,939,809. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01. Incyte Corporation has a 12 month low of $98.49 and a 12 month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. Incyte Corporation had a negative net margin of 10.90% and a negative return on equity of 12.91%. The firm’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.19 earnings per share. analysts anticipate that Incyte Corporation will post -1.3 EPS for the current fiscal year.

Incyte Corporation Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.